Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MCAR -- Ignore unavailable to you. Want to Upgrade?

To: LEE SWIFT who wrote (445)	11/24/1999 4:19:00 PM
From: LORD ERNIE	Read Replies (1) \| Respond to of 467

+ 164% at the close. Not bad for a nasdaq stock :-))) Maybe it is on the news: MedCare Technologies, Inc. Announces RxSheets.com Receives Strong Response from Physicians OAK BROOK, Ill., Nov 23, 1999 (BUSINESS WIRE) -- MedCare Tech(NASDAQ: MCAR) MedCare Technologies, Inc. (NASDAQ: MCAR) announced today that its online business, RxSheets.com (www.rxsheets.com), has received overwhelming response from physicians throughout the country. The Company launched its pharmaceutical focused site for physicians in October and began its marketing campaign on November 15th. During the first five days, the Company received thousands of physician requests to enroll in its program every day. "The response from the medical community has been tremendous," said Jeff Aronin, President and Chief Executive Officer. "RxSheets.com will revolutionize the way doctors across the country will request their pharmaceutical samples. This is the best online product that caters to the physician's pharmaceutical needs by providing an easy alternative to request and deliver samples in a prompt manner. In addition, the site delivers timely concise industry related information. Unlike all the other physician-focused sites, Rxsheets has the ability to get physicians online and using the site. Based on the multi-billion dollar value of the physician marketplace to pharmaceutical and medical companies, we believe Rxsheets can be an extremely profitable and lucrative business. We are not aware of any physician site that has received the excitement and response from the physician community." Exclusively designed for the physician, RxSheets.com offers a wide array of compelling and focused information and services, including drug sample requests, drug protocols and studies, research information and other pertinent aspects of the pharmaceutical market. The site will also offer a healthcare calendar of events, educational opportunities and a weekly pharmaceutical newsletter. MedCare Technologies, Inc. is a healthcare technology service company that focuses on under-served high growth markets. The Company's RxSheets.com (www.rxsheets.com), offers a wide array of compelling and focused information and services, including drug sample requests for physicians, drug protocols and studies, research information, and other pertinent aspects of the $270 billion worldwide pharmaceutical market. The Company began by developing the MedCare Program, now the nations leading conservative therapy for treating urinary incontinence, a hidden health condition that, at approximately $26 billion, costs more than diabetes and bypass surgery combined. This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements which are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, changes in insurance reimbursement, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

To: LEE SWIFT who wrote (445)	11/24/1999 4:21:00 PM
From: LORD ERNIE	Respond to of 467

Or is it the upgrade from Dutton??? NEW YORK, Nov 22, 1999 (BUSINESS WIRE) -- A Quarterly update report covering MedCare Technologies, Inc. (Nasdaq: MCAR) by PAR Analyst John M. Dutton was released today for Public Analysis & Review (PAR). PAR is the unique professional independent security analyst program administered by the non-profit Investors Research Institute, Inc., and Investrend Research distributes the PAR program reports. According to Gayle Essary, Investrend Research president, Mr. Dutton established a NEUTRAL rating on the stock. However, Mr. Dutton noted, this rating would be increased to BUY if their new business model for the MedCare Program and Rxsheets.com is able to produce expected results in the next several months. A copy of the Quarterly Review Report, also in Adobe pdf format, is available from the Investrend web site at www.investrend.com. A summary of Mr. Dutton's conclusions follows: A NEUTRAL rating on the shares of MedCare rating reflects the lack of positive operating results since May, with reported results substantially below our projected levels. However, we note that there have been many potentially positive changes to the Company's business models. As results under the new models become apparent, the neutral stock rating will be revisited. MedCare Technologies and its MedCare program, is the largest program using behavioral modification to treat incontinence. This approach is endorsed by the AMA and the US Dept. of Health Services. The Company has now targeted the hospital market as the primary market to base its MedCare Program. Two excellent hospitals as of this date have signed with MCAR. Management believes it will shortly announce a third. We believe they are on the right track. By any measure, the incontinence treatment market is in billions of dollars annually. The MedCare Program benefits all concerned, patient, doctor, and insurance provider. The market is untapped except for the less desirable alternatives of pharmacological and surgery. In the middle of changing its MedCare Program business model, major changes were made to its original Internet based program, Medcareonline. This was replaced with an interesting physician service called Rxsheets.com announced during the recent quarter. Results in the form of partnering with drug companies are expected in the next several months. The present NEUTRAL rating on the stock reflects the need of the Company to demonstrate results under its new business models. We believe the Company may at last be on the right track, in which case the stock rating will be revisited.